Details of the Drug Combinations

General Information of This Drug (ID: DMGB5RE)

Drug Name
Tranylcypromine   DMGB5RE
Synonyms
GJZ; Jatrosom; Parnate; Parnitene; Tranilcipromina; Transamine; Tranylcyprominum; Allphar Brand of Tranylcypromine Sulfate; Esparma Brand of Tranylcypromine Sulfate; GlaxoSmithKline Brand of Tranylcypromine Sulfate; Goldshield Brand of Tranylcypromine Sulfate; Link Brand of Tranylcypromine Sulfate; Racemic Tranylcypromine; SmithKline Brand of Tranylcypromine Sulfate; SKF 385; Trans 2 Phenylcyclopropylamine; D-Tranylcypromine; Dl-Tranylcypromine; Jatrosom (TN); L-Tranylcypromine; Parmodalin (TN); Parnate (TN); Parstelin (TN); SKF Trans-385; Sicoton (TN); Sulfate, Tranylcypromine; Tranilcipromina [INN-Spanish]; Transamine (TN); Transapin (TN); Tranylcypromine (INN); Tranylcypromine [INN:BAN]; Tranylcyprominum [INN-Latin]; Tylciprine (TN); Trans-2-Phenylcyclopropylamine; Trans-DL-2-Phenylcyclopropylamine; Trans-(-)-2-Phenylcyclopropanamine; Cyclopropanamine, 2-phenyl-, (1R-trans)-(9CI); (+)-(R)-Tranylcypromine; (+)-Tranylcypromine; (+)-trans-2-Phenylcyclopropylamine; (-)-Tranylcypromine; (1R)-2-phenylcyclopropan-1-amine; (1R,2R)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropanamine; (1S)-2-phenylcyclopropan-1-amine; (1S,2R)-2-phenylcyclopropan-1-amine; (1S,2S)-2-phenylcyclopropan-1-amine; (2S)-2-phenylcyclopropan-1-amine; 2-Phenylcyclopropanamine; 2-phenylcyclopropan-1-amine
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Approved [1]
Prostate cancer 2C82.0 Patented [2]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

11 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
BGT226 + Tranylcypromine DC6QNO3 BGT226 Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + Tranylcypromine DCD4SM1 KN-62 DD2 (Cell Line: DD2) [4]
Tranylcypromine + Clindamycin DC10B7U Clindamycin Hepatoblastoma (Cell Line: HB3) [4]
Tranylcypromine + BIX-01294 DCMS5SX BIX-01294 DD2 (Cell Line: DD2) [4]
Tranylcypromine + BIX-01294 DCRJQ73 BIX-01294 Hepatoblastoma (Cell Line: HB3) [4]
Tranylcypromine + Berberine DCOVEHQ Berberine DD2 (Cell Line: DD2) [4]
Tranylcypromine + Midostaurin DC6P5L0 Midostaurin Hepatoblastoma (Cell Line: HB3) [4]
Tranylcypromine + Artemisinin DC780XC Artemisinin Hepatoblastoma (Cell Line: HB3) [4]
Tranylcypromine + Chloroquine DCTTOUD Chloroquine DD2 (Cell Line: DD2) [4]
Tranylcypromine + Quinine DCUY14O Quinine Hepatoblastoma (Cell Line: HB3) [4]
Tranylcypromine + Nitisinone DCTDS34 Nitisinone DD2 (Cell Line: DD2) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DrugCom(s)
1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Liothyronine + Tranylcypromine DC51VK7 Liothyronine Major Depression [5]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 ClinicalTrials.gov (NCT00296686) Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression